The Relationship Between Triglyceride to High-Density Lipoprotein Cholesterol Ratio and Cardiovascular High-Risk: A Cross-Sectional Investigation

Yapeng Li,[1] Huiting Shi,[1] Cui Liang,[1] Qiaotao Xie,[2] Baocang Lei,[2]

Haowei Hu,[3] Haoran Wang,[2] Pengcheng Li,[1]

[1]The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China

[2]Luohe Central Hospital, Luohe Medical College, Luohe, China

[3]Leicester International Institute, Dalian University of Technology, Dalian, China

Corresponding to: Pengcheng Li, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China

Alternate corresponding author: Haoran Wang, Luohe Central Hospital, Luohe Medical College, Luohe, China

Abstract

Aims

The triglyceride to high-density lipoprotein cholesterol (TG/HDL-C) ratio reflects the balance between atherogenic and anti-atherogenic lipid fractions. The study aims to investigate the utility of the TG/HDL-C ratio in identifying high-risk groups for cardiovascular disease (CVD) within the general population.

Methods

The current study was a branch of the ChinaHEART cohort in middle China that involved a total of 6,593 community-dwelling adults. We examine the association between TG/HDL-C and CVD high-risk in a cross-sectional investigation.

Results

Results from restricted cubic spline and ROC analyses revealed a significant relationship between higher TG/HDL-C levels and increased odds of cardiovascular high-risk, with the ratio exhibiting good discriminatory power (AUC=0.819 in the fully adjusted model). Logistic

regression further supported this association, indicating a 1.21-fold rise in

the odds of high-risk for each unit increase in TG/HDL-C.

Conclusions

The TG/HDL ratio demonstrates potential as a valuable clinical tool for

CVD prevention. By incorporating the TG/HDL ratio into risk assessment

models, healthcare professionals can enhance risk stratification and

identify high-risk individuals who may benefit from targeted

interventions.

Key words:

TG/HDL-C ratio; cardiovascular high-risk; cross-sectional study; public

health.

Introduction

Cardiovascular diseases (CVD) continue to be a leading cause of

mortality and morbidity worldwide, imposing a significant burden on

healthcare systems and society as a whole. Early identification of

individuals at high risk of developing CVD is crucial for implementing

targeted prevention and management strategies.(2) Traditional risk factors

such as hypertension, dyslipidemia, smoking, and diabetes have been

widely recognized, but there is a growing interest in exploring novel

biomarkers that may enhance risk stratification in the general

population.(3)

In recent years, the triglyceride to high-density lipoprotein cholesterol

(TG/HDL-C) ratio has emerged as a potential marker for cardiovascular

risk assessment.(4–8) This ratio reflects the balance between atherogenic

and anti-atherogenic lipid fractions. and has been proposed as a simple

and cost-effective tool to identify individuals at increased risk of CVD.

Some studies have found that this indicator is associated with morbidity

and mortality from cardiovascular disease.(4,9) However, there is still a

lack of relevant studies on whether this indicator can identify high-risk

groups of cardiovascular disease in the general population.

Our study aims to address this gap in knowledge by conducting a cross-

sectional observational study to evaluate the utility of the TG/HDL-C

ratio in identifying high-risk individuals for cardiovascular diseases in the

general population. By examining this novel biomarker in a large and

diverse sample, we seek to elucidate its potential as a screening tool for

early risk stratification and intervention. If we can effectively identify

individuals at high risk of cardiovascular disease in the general

population using this indicator, we can intervene at earlier stages of

cardiovascular disease, thereby maximizing the prevention of major

adverse cardiovascular events.

Methods

Study population and data collection

The current study is a branch of the China Health Evaluation And risk

Reduction through nationwide Teamwork (ChinaHEART) in Luohe City,

involving 6,859 community-dwelling adults recruited from two township

hospitals in Luohe City between November 2, 2021 and February 20,

2022. The ChinaHEART cohort is a population cohort launched by the

China National Center for Cardiovascular Diseases (NCCD) initially

aiming at cardiovascular disease (CVD) risk screening and

management.(10) Study methods has been described previously.(11) The

study strictly adhered to ethical guidelines, with approval granted by the

Ethics Committee of Fuwai Hospital and the Ethics Committee of Luohe

Central Hospital. Participants received detailed information on the study's

purpose, significance, and risks before participant, in accordance with the

Declaration of Helsinki. Written informed consent was obtained from all

participants. The inclusion criteria for this study are as follows: (1) Age:

35-75 years (born between January 1, 1946, and December 31, 1986); (2)

Residing near the survey site for at least 6 months in the 12 months prior

to screening; (3) Voluntarily participating in this project and signing the

informed consent form. The exclusion criteria are as follows: (1) Survey

participants with missing data; (2) Survey participants who answered

"unclear" to questionnaire items; (3) Survey participants with fasting time

less than 8 hours before blood collection.

We utilized standardized questionnaires to collect data on socio-

demographic characteristics (e.g., age, gender), lifestyle factors (e.g.,

smoking, alcohol consumption), medical history (including hypertension,

diabetes, dyslipidemia, coronary heart disease, myocardial infarction,

stroke), and medication usage (such as antihypertensive, hypoglycemic,

and lipid-lowering drugs) of the study participants. Data were collected

through an information system provided by the ChinaHEART study and

was uploaded directly to the national study center in the Fuwai Hospital.

The anonymous data used in the current study was applied from the

national study center in the Fuwai Hospital after they performed data

washing. Cardiovascular disease (CVD) was defined as a diagnosis of

coronary heart disease, previous myocardial infarction, or stroke. Body

mass index (BMI) was calculated as body mass in kilograms divided by

the square of height in meters. Waist circumference was measured by

placing a measuring tape horizontally around the abdomen at the

midpoint between the anterior superior iliac crest and the lower edge of

the twelfth rib. Systolic blood pressure (SBP) and diastolic blood pressure

(DBP) were measured in a seated resting position at least twice, and the

average values were recorded. Lipid profiles were assessed using

fingertip blood samples.

According to the risk assessment prediction map in the Guidelines

for Cardiovascular Risk Assessment and Management issued by the

World Health Organization in 2008, the risk assessment of cardiovascular

disease was conducted.(12) If the screening subjects had 10 years of risk

of cardiovascular disease 20%, they were judged as high risk.

Statistics

Statistics

The study population was categorized based on quartiles of the TG/HDL-

C ratio for basic characteristic description. Normality of continuous

variables was assessed using the Kolmogorov-Smirnov test, with mean ±

standard deviation for normally distributed data, and median (25%-75%

interval) for non-normally distributed data. Categorical variables were

described using percentages. Distribution differences in high

cardiovascular risk proportions across TG/HDL-C ratio quartile

populations were illustrated with a percentage stacking bar graph.

Continuous variable comparisons between groups involved t-tests or

analysis of variance for normally distributed data, and rank sum tests for

non-normally distributed data. Chi-square tests were conducted for

categorical variable comparisons. The association between the TG/HDL-

C ratio and cardiovascular high risk was examined using logistic

regression analysis, with two models utilized: one without confounder

adjustments for univariate analysis, and another adjusting for

confounding factors including gender, age, marital status, BMI, waist

circumference, fasting blood glucose, smoking history, alcohol

consumption history, diabetes, and systolic and diastolic blood pressure.

Nonlinear associations between the TG/HDL-C ratio and cardiovascular

risk were explored through restricted cubic spline analysis, utilizing key

points at the 10th, 25th, 50th, 75th, and 90th percentiles of the TG/HDL-

C ratio. The ability of the TG/HDL-C ratio to identify high cardiovascular

risk was evaluated using receiver operating characteristic (ROC) curve

analysis. While conducting the ROC curve analysis, we calculated the

appropriate cutoff value, and this cutoff value was used to divide the

participants into the high and low TG/HDL-C groups for further logistic

regression analysis. Furthermore, we used net reclassification

improvement (NRI) index to quantify the added value of TG/HDL-C for

the discriminative performance.

Results

A total of 6,593 participants with sufficient data were included in the

study, comprising 1,417 individuals categorized as cardiovascular high-

risk and 5,176 individuals in the non-high-risk category. The study cohort

was stratified into four segments based on the TG/HDL-C ratio,

highlighting notable variations in demographic and clinical characteristics

such as age, gender, height, weight, BMI, waist circumference, smoking

habits, alcohol consumption, history of hypertension, diabetes, as well as

levels of glucose, lipids, and blood pressure (refer to Table 1). The

distribution of high-risk individuals across these quartiles was 16%, 15%,

18%, and 38% respectively (view Figure 1).

To explore the nonlinear relationship between the TG/HDL-C ratio

and cardiovascular high-risk, a restricted cubic spline analysis was

conducted. The analysis revealed a positive association between elevated

TG/HDL-C ratio levels and an increased likelihood of cardiovascular

high-risk (see Figure 2).

The TG/HDL-C ratio's discriminatory ability in identifying

individuals at cardiovascular high-risk was evaluated through ROC

analysis (refer to Figure 3). Initially, in model 1, the AUC for the

TG/HDL-C ratio alone was 0.562 (95% CI 0.544-0.580) for all

participants. However, upon incorporating all covariates into the analysis

in model 2, the AUC significantly increased to 0.819 (95% CI 0.805-

0.834), suggesting the enhanced effectiveness of combining the TG/HDL-

C ratio with traditional cardiovascular risk factors for high-risk

identification. Notably, the NRI index showed a significant improvement

in discriminative performance, with a value of 0.107 ± 0.030 (p = 0.016).

Moreover, the ROC analysis identified the optimal cutoff value for the

TG/HDL-C ratio as 1.18, enabling the classification of participants into

high and low TG/HDL-C ratio groups.

The logistic regression analysis results examining the relationship

between the TG/HDL-C ratio and cardiovascular high-risk are detailed in

Table 2. In Model 1, a 1 unit increase in the TG/HDL-C ratio was

associated with a 1.40-fold increase in the odds of cardiovascular high-

risk (95% CI 1.30-1.51, $p < 0.001$). Comparatively, the high TG/HDL-C

ratio group exhibited 1.61 times higher odds of high-risk than the low

TG/HDL-C ratio group (95% CI 1.43-1.81, $p < 0.001$), while the highest

quartile of the TG/HDL-C ratio had 1.79 times higher odds compared to

the lowest quartile (95% CI 1.52-2.10, $p < 0.001$). In Model 2, each 1 unit

rise in the TG/HDL-C ratio was associated with a 1.21-fold increase in

the odds of cardiovascular high-risk (95% CI 1.11-1.32, $p < 0.001$).

Additionally, the high TG/HDL-C ratio group demonstrated 1.27 times

higher odds of high-risk compared to the low TG/HDL-C ratio group

(95% CI 1.10-1.47, p = 0.001), with the highest quartile of the TG/HDL-

C ratio displaying 1.49 times higher odds than the lowest quartile (95%

CI 1.21-1.83, p < 0.001).

Discussion

Cardiovascular disease (CVD) remains a significant global health burden,

necessitating the identification of individuals at high risk for effective

prevention and intervention strategies. The TG/HDL-C ratio has emerged

as a potential marker for assessing cardiovascular risk in the general

population. It has been observed that the ratio of TG/HDL-C ratio not

only provides an approximation of insulin resistance but also assists in

identifying patients with an atherogenic lipoprotein profile.(13) The

typical lipoprotein phenotype in insulin-resistant/hyperinsulinemic

patients is typified by high plasma TG and low HDL cholesterol levels,

smaller and denser LDL particles, as well as an increased accumulation of

remnant lipoproteins after a meal. This lipoprotein phenotype is not only

associated with insulin resistance, but it is also linked with an elevated

risk of cardiovascular disease.(14) Although plasma TG and HDL

cholesterol levels are commonly tested, the same cannot be said for the

LDL particle diameter or postprandial remnant concentrations.

Nonetheless, a previous study observed a robust correlation between the

TG/HDL cholesterol ratio and the LDL peak diameter.(15) Moreover, it

is suggested that a TG/HDL cholesterol concentration ratio of 3.5 can

accurately predict the presence of the small dense LDL phenotype (LDL

phenotype B). Therefore, by assessing plasma TG and HDL cholesterol

levels and computing their ratio, it is possible to obtain understanding

into three out of the four modifications in lipoprotein metabolism that

enhance the risk of cardiovascular disease in insulin-resistant patients.

Numerous epidemiological studies have examined the relationship

between the TG/HDL ratio and CVD risk. Most of these studies have

reported a positive association between a higher TG/HDL ratio and

increased CVD risk. For instance, a prospective cohort study by Gaziano

et al. found the ratio of triglycerides to HDL was a strong predictor of

myocardial infarction;(16) Urbina et al. suggests the TG/HDL ratio may

be a useful marker for identifying young individuals at risk for

developing arterial stiffness, an early sign of CVD;(17) Li et al. found a

positive correlation between the TG/HDL-C ratio and carotid intima

thickness, a marker of early atherosclerosis, in adolescents with type 2

diabetes;(18) Du et al. found that the TG/HDL ratio is associated with

insulin resistance, a major risk factor for CVD, in a Chinese

population;(19) Ren et al. found that the TG/HDL ratio is positively

associated with insulin resistance in newly diagnosed type 2 diabetes

patients, indicating an increased risk of CVD;(20) Squillace et al. found

that a higher TG/HDL ratio is predictive of the development of diabetes,

a major risk factor for CVD;(21) Hong et al. found that a high TG/HDL

ratio is associated with an increased risk of cardiovascular events in

patients with diabetes and coronary artery disease.(22)

The TG/HDL ratio holds clinical significance as a potential marker

for CVD prevention. It provides valuable insights into the balance

between TG and HDL levels, representing the interplay between

dyslipidemia and atherosclerosis. A higher TG/HDL ratio reflects an

increased atherogenic lipid profile and has been associated with arterial

stiffness, carotid intima thickness, insulin resistance and diabetes, all of

which contribute to CVD development. By incorporating the TG/HDL

ratio into risk assessment models, clinicians can more accurately identify

individuals at high risk for CVD and implement targeted interventions.

Despite the clinical significance of the TG/HDL ratio, several

limitations must be acknowledged. First, the cut-off values for defining

high TG/HDL ratios vary across studies, leading to heterogeneity in

research findings. Standardization of these thresholds is necessary to

ensure consistency and comparability between studies. Additionally,

confounding factors, including age, sex, lifestyle factors, and

comorbidities, may influence the association between the TG/HDL ratio

and CVD risk. Although some studies have attempted to account for these

factors, further research is needed to elucidate their precise impact.

Moreover, variations in laboratory methods for lipid profile assessment

may introduce measurement errors and affect the accuracy of TG and

HDL cholesterol estimations.

In conclusion, the TG/HDL ratio demonstrates potential as a

valuable clinical tool for CVD prevention. Its ability to capture the

interplay between triglycerides and HDL cholesterol provides a

comprehensive assessment of the atherogenic lipid profile. By

incorporating the TG/HDL ratio into risk assessment models, healthcare

professionals can enhance risk stratification and identify high-risk

individuals who may benefit from targeted interventions. However,

standardization of cut-off values, better control of confounding factors,

and harmonization of laboratory methods are needed to further validate

the clinical significance of the TG/HDL ratio. With these advancements,

the TG/HDL ratio could significantly contribute to the prevention and

control of cardiovascular disease.

Availability of data and materials

The data that support the findings of this study are available from the

corresponding author Pengcheng Li and Haoran Wang, upon reasonable

request.

Declaration of Interest statement

The authors declared that there is no conflict of interest.

Author Contributions statement

Conceptualization and Methodology: Haoran Wang, Pengcheng Li;

Formal analysis: Yapeng Li, Huiting Shi, Cui Liang, Baocang Lei,

Haowei Hu; Data Curation: Cui Liang, Qiaotao Xie, Baocang Lei,

Haowei Hu, Haoran Wang, Pengcheng Li; Writing: Yapeng Li, Huiting

Shi, Cui Liang, Pengcheng Li; Funding acquisition: Qiaotao Xie, Haoran

Wang, Pengcheng Li.

Fundings

The study is supported by grants from the National Natural Science

Foundation of China (81803318, 82304229), Henan Provincial Science

and Technology Research Project (212102310813), Henan Educational

Committee (22B320003), and Luohe ministry of science and technology

(20210110). The funders have no role in the design and implementation

of the current study.

Ethical statement

This study was conducted with approval from the Ethics Committee of

Fuwai Hospital (2014–574) as the Central Ethic, and was approved by the

Ethics Committee of Luohe Central Hospital as the local ethic. This study

was conducted in accordance with the declaration of Helsinki. Written

informed consent was obtained from all participants.

References

1. Roth GA, Mensah GA, Johnson CO, Addolorato G, Ammirati E,
Baddour LM, Barengo NC, Beaton AZ, Benjamin EJ, Benziger CP,
et al. Global Burden of Cardiovascular Diseases and Risk Factors,
1990-2019: Update From the GBD 2019 Study. *J Am Coll Cardiol*
(2020) 76:2982–3021. doi: 10.1016/j.jacc.2020.11.010

2. Zhao D, Liu J, Xie W, Qi Y. Cardiovascular risk assessment: a
global perspective. *Nat Rev Cardiol* (2015) 12:301–311. doi:
10.1038/nrcardio.2015.28

3. Thupakula S, Nimmala SSR, Ravula H, Chekuri S, Padiya R.
Emerging biomarkers for the detection of cardiovascular diseases.
Egypt Heart J (2022) 74:77. doi: 10.1186/s43044-022-00317-2

4. Yang M, Rigdon J, Tsai SA. Association of triglyceride to HDL
cholesterol ratio with cardiometabolic outcomes. *J Investig Med Off*
Publ Am Fed Clin Res (2019) 67:663–668. doi: 10.1136/jim-2018-
000869

5. Kosmas CE, Rodriguez Polanco S, Bousvarou MD,
Papakonstantinou EJ, Peña Genao E, Guzman E, Kostara CE. The
Triglyceride/High-Density Lipoprotein Cholesterol (TG/HDL-C)
Ratio as a Risk Marker for Metabolic Syndrome and Cardiovascular
Disease. *Diagnostics* (2023) 13:929. doi:
10.3390/diagnostics13050929

6. Che B, Zhong C, Zhang R, Pu L, Zhao T, Zhang Y, Han L.
Triglyceride-glucose index and triglyceride to high-density
lipoprotein cholesterol ratio as potential cardiovascular disease risk
factors: an analysis of UK biobank data. *Cardiovasc Diabetol* (2023)
22:34. doi: 10.1186/s12933-023-01762-2

7. Chen C, Dai J-L. Triglyceride to high-density lipoprotein cholesterol
(HDL-C) ratio and arterial stiffness in Japanese population: a
secondary analysis based on a cross-sectional study. *Lipids Health*
Dis (2018) 17:130. doi: 10.1186/s12944-018-0776-7

8.   Chen Y, Chang Z, Liu Y, Zhao Y, Fu J, Zhang Y, Liu Y, Fan Z.
Triglyceride to high-density lipoprotein cholesterol ratio and
cardiovascular events in the general population: A systematic review
and meta-analysis of cohort studies. *Nutr Metab Cardiovasc Dis*
NMCD (2022) 32:318–329. doi: 10.1016/j.numecd.2021.11.005

9.   Chen Z, Chen G, Qin H, Cai Z, Huang J, Chen H, Wu W, Chen Z,
Wu S, Chen Y. Higher triglyceride to high-density lipoprotein
cholesterol ratio increases cardiovascular risk: 10-year prospective
study in a cohort of Chinese adults. *J Diabetes Investig* (2020)
11:475–481. doi: 10.1111/jdi.13118

10. Wang R, Yang Y, Lu J, Cui J, Xu W, Song L, Wu C, Zhang X, Dai
H, Zhong H, et al. Cohort Profile: ChinaHEART (Health Evaluation
And risk Reduction through nationwide Teamwork) Cohort. *Int J*
Epidemiol (2023) 52:e273–e282. doi: 10.1093/ije/dyad074

11. Lu J, Xuan S, Downing NS, Wu C, Li L, Krumholz HM, Jiang L.
Protocol for the China PEACE (Patient-centered Evaluative
Assessment of Cardiac Events) Million Persons Project pilot. *BMJ*
Open (2016) 6:e010200. doi: 10.1136/bmjopen-2015-010200

12. WHO CVD Risk Chart Working Group. World Health Organization
cardiovascular disease risk charts: revised models to estimate risk in
21 global regions. *Lancet Glob Health* (2019) 7:e1332–e1345. doi:
10.1016/S2214-109X(19)30318-3

13. Reaven GM. The insulin resistance syndrome. *Curr Atheroscler Rep*
(2003) 5:364–371. doi: 10.1007/s11883-003-0007-0

14. Lorenzatti AJ, Toth PP. New Perspectives on Atherogenic
Dyslipidaemia and Cardiovascular Disease. *Eur Cardiol* (2020)
15:1–9. doi: 10.15420/ecr.2019.06

15. Dobiásová M, Frohlich J. The plasma parameter log (TG/HDL-C) as
an atherogenic index: correlation with lipoprotein particle size and
esterification rate in apoB-lipoprotein-depleted plasma (FER(HDL)).
Clin Biochem (2001) 34:583–588. doi: 10.1016/s0009-
9120(01)00263-6

16.   Gaziano JM, Hennekens CH, O'Donnell CJ, Breslow JL, Buring JE.
Fasting triglycerides, high-density lipoprotein, and risk of myocardial
infarction. *Circulation* (1997) 96:2520–2525. doi:
10.1161/01.cir.96.8.2520

17.   Urbina EM, Khoury PR, McCoy CE, Dolan LM, Daniels SR,
Kimball TR. Triglyceride to HDL-C ratio and increased arterial
stiffness in children, adolescents, and young adults. *Pediatrics* (2013)
131:e1082-1090. doi: 10.1542/peds.2012-1726

18.   Li X, Deng Y-P, Yang M, Wu Y-W, Sun S-X, Sun J-Z. Triglyceride
to high-density lipoprotein cholesterol ratio and carotid intima-
medial thickness in Chinese adolescents with newly diagnosed type 2
diabetes mellitus. *Pediatr Diabetes* (2016) 17:87–92. doi:
10.1111/pedi.12250

19.   Du T, Yuan G, Zhang M, Zhou X, Sun X, Yu X. Clinical usefulness
of lipid ratios, visceral adiposity indicators, and the triglycerides and
glucose index as risk markers of insulin resistance. *Cardiovasc*
Diabetol (2014) 13:146. doi: 10.1186/s12933-014-0146-3

20.   Ren X, Chen ZA, Zheng S, Han T, Li Y, Liu W, Hu Y. Association
between Triglyceride to HDL-C Ratio (TG/HDL-C) and Insulin
Resistance in Chinese Patients with Newly Diagnosed Type 2
Diabetes Mellitus. *PloS One* (2016) 11:e0154345. doi:
10.1371/journal.pone.0154345

21.   Squillace N, Lorenzini P, Lapadula G, Bandera A, Cozzi-Lepri A,
Rusconi S, Puoti M, Castagna A, Antinori A, Gori A, et al.
Triglyceride/HDL ratio and its impact on the risk of diabetes mellitus
development during ART. *J Antimicrob Chemother* (2016) 71:2663–
2669. doi: 10.1093/jac/dkw185

22.   Yang S-H, Du Y, Li X-L, Zhang Y, Li S, Xu R-X, Zhu C-G, Guo Y-
L, Wu N-Q, Qing P, et al. Triglyceride to High-Density Lipoprotein
Cholesterol Ratio and Cardiovascular Events in Diabetics With
Coronary Artery Disease. *Am J Med Sci* (2017) 354:117–124. doi:
10.1016/j.amjms.2017.03.032

Tables

Table 1. Clinical characteristics of the study population by quartiles of TG/HDL-C.

	Q1	Q2	Q3	Q4	p-value
Number	N=1,648	N=1,648	N=1,648	N=1,649	
Age (median (IQR))	59.00 (50.00-67.00)	58.00 (50.00-67.00)	58.00 (51.00-66.00)	58.00 (52.00-66.00)	0.78
Male (%)	617 (37%)	613 (37%)	599 (36%)	667 (40%)	0.081
BMI (median (IQR))	24.12 (22.14-26.32)	24.80 (22.70-26.83)	25.15 (23.16-27.44)	26.04 (24.01-28.36)	<0.001
Waist (median (IQR))	83.00 (77.00-89.95)	85.00 (79.00-91.00)	86.00 (80.50-93.00)	89.00 (82.00-95.00)	<0.001
SBP (median (IQR))	135.00 (123.25-148.50)	136.00 (124.50-149.50)	136.00 (125.50-149.50)	141.50 (129.50-152.00)	<0.001
DBP (median (IQR))	82.50 (76.00-89.50)	82.50 (76.00-89.50)	82.50 (76.00-90.00)	85.00 (77.00-92.50)	<0.001
Current smoke (%)	338 (21%)	325 (20%)	300 (18%)	358 (22%)	0.083
Drinking (%)	86(5%)	68(4%)	98(6%)	107(6%)	0.018
HTN (%)	335(20%)	338(21%)	367(22%)	467(28%)	<0.001
DM (%)	72(4%)	96(6%)	91(6%)	147(9%)	<0.001
CHD (%)	36(2%)	25(2%)	19(1%)	13(1%)	0.006
Stroke (%)	63(4%)	37(2%)	41(2%)	40(2%)	0.021
TC (median (IQR))	4.08 (3.47-4.65)	4.53 (4.03-5.11)	4.97 (4.36-5.43)	5.62 (4.98-6.39)	<0.001
HDL (median (IQR))	1.71 (1.49-1.97)	1.50 (1.33-1.69)	1.39 (1.23-1.52)	1.21 (1.09-1.37)	<0.001
TG (median (IQR))	1.21 (0.95-1.62)	1.41 (1.11-1.74)	1.58 (1.25-2.00)	1.94 (1.47-2.69)	<0.001
LDL (median (IQR))	1.96 (1.45-2.44)	2.48 (2.09-2.88)	2.71 (2.32-3.17)	3.35 (2.71-4.03)	<0.001
Glu (median (IQR))	5.40 (5.10-5.80)	5.40 (5.10-5.90)	5.40 (5.11-6.00)	5.70 (5.30-6.40)	<0.001
TG/HDL-C (median (IQR))	2.43 (2.20-2.59)	3.02 (2.88-3.15)	3.55 (3.41-3.72)	4.50 (4.17-4.97)	<0.001
CVD_highrisk (%)	257 (16%)	251 (15%)	290 (18%)	620 (38%)	<0.001

Data are presented as median (IQR) for continuous variables, and number (percentage) for categorical variables. HTN, hypertension; DM, diabetes mellitus;

CHD, coronary heart disease; BMI, body mass index; TC, total cholesterol; TG, triglyceride; LDL, low density lipoprotein; HDL, high density lipoprotein;

SBP, systolic blood pressure; DBP, diastolic blood pressure.

Table 2. Association between TG/HDL-C ratio and cardiovascular high-risk by logistic regression.

	Model 1		Model 2	
	OR (95% CI)	p	OR (95% CI)	p
All participants				
TG/HDL-C (per 1 unit)	1.40 (1.30-1.51)	<0.001	1.21 (1.11-1.32)	<0.001
TG/HDL-C (high vs low)	1.61 (1.43-1.81)	<0.001	1.27 (1.10-1.47)	0.001
TG/HDL-C (quartile)				
Q1	Ref		Ref	
Q2	0.90 (0.75-1.07)	0.214	1.04 (0.85-1.29)	0.68
Q3	0.84 (0.71-1.01)	0.06	0.95 (0.77-1.18)	0.634
Q4	1.79 (1.52-2.10)	<0.001	1.49 (1.21-1.83)	<0.001
Female				
TG/HDL-C (per 1 unit)	1.36 (1.24-1.50)	<0.001	1.14 (1.01-1.28)	0.028
TG/HDL-C (high vs low)	1.52 (1.30-1.77)	<0.001	1.16 (0.96-1.40)	0.114
TG/HDL-C (quartile)				
Q1	Ref		Ref	
Q2	0.94 (0.74-1.19)	0.6	0.97 (0.74-1.28)	0.838
Q3	0.91 (0.72-1.15)	0.447	1.00 (0.76-1.32)	0.998
Q4	1.78 (1.44--2.20)	<0.001	1.33 (1.02-1.74)	0.034
Male				
TG/HDL-C (per 1 unit)	1.50 (1.33-1.69)	<0.001	1.31 (1.14-1.52)	<0.001
TG/HDL-C (high vs low)	1.82 (1.51-2.19)	<0.001	1.45 (1.15-1.84)	<0.001
TG/HDL-C (quartile)				
Q1	Ref		Ref	
Q2	0.85 (0.66-1.11)	0.238	1.14 (0.84-1.57)	0.432
Q3	0.78 (0.59-1.03)	0.076	0.90 (0.64-1.27)	0.557
Q4	1.94 (1.51-2.49)	<0.001	1.67 (1.20-2.32)	0.002

Figure legends

Figure 1. Percentage stacked histogram to visually represent the distribution of cardiovascular high-risk individuals across quartiles of the TG/HDL-C ratio.

Figure 2. Restricted cubic spline to assess the non-liner relationship between TG/HDL-C ratio and cardiovascular high-risk.

Figure 3. ROC curve to illustrate the discriminatory power of TG/HDL-C for cardiovascular high-risk.

Fig 1

Figure 2. Restricted cubic spline to assess the non-liner relationship between TG/HDL-C ratio and cardiovascular high-risk.

Fig 2

Fig 3